New Gene Technology Assesses Nine Genes that may Predict Response to Panitumumab
June 2nd 2010
Although KRAS gene mutation is a well-established biomarker for a lack of response to anti-epidermal growth factor receptor (anti-EGFR) antibodies in colorectal cancer, a study presented at the AACR 101st Annual Meeting 2010 sought to determine whether mutations in 9 genes known to be mutated in colorectal cancer, including AKT1, BRAF, CTNNB1, EGFR, KRAS (exon 3), NRAS, PIK3CA, PTEN, and TP53, could also predict response to Vectibix (panitumumab) in patients with metastatic colorectal cancer.